Skip to main content

RELMADA THERAPEUTICS INC

For the period ended Mar 31, 2024. Filed May 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

RLMD$3.90+3.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended** March 31,2024**

or

☐** TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _______________________ to ___________________________

Commission File Number:000-55347

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada45-5401931
(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.)
2222 Ponce de Leon, Floor 3 Coral Gables, FL33134
(Address of Principal Executive Offices)(Zip Code)

(786) 629-1376

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.001 par value per shareRLMDThe NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.☒ Yes No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).☒ Yes No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐ Yes☒ No

As of May 3, 2024, there were 30,174,202 shares of common stock, $0.001 par value per share, outstanding.

Index

Page Number
PART I - FINANCIAL INFORMATION
Item 1.Unaudited Condensed Consolidated Financial Statements1
Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 20231
Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 20232
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2024 and 20233
Unaudited Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 20234
Notes to Unaudited Condensed Consolidated Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations12
Item 3.Quantitative and Qualitative Disclosures About Market Risk20
Item 4.Controls and Procedures20
PART II - OTHER INFORMATION
Item 1.Legal Proceedings21
Item 1A.Risk Factors21
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds21
Item 3.Defaults Upon Senior Securities21
Item 4.Mine Safety Disclosures21
Item 5.Other Information21
Item 6.Exhibits22
SIGNATURES23

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.